Literature DB >> 21718788

Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease.

Andrea Chincarini1, Paolo Bosco, Piero Calvini, Gianluca Gemme, Mario Esposito, Chiara Olivieri, Luca Rei, Sandro Squarcia, Guido Rodriguez, Roberto Bellotti, Piergiorgio Cerello, Ivan De Mitri, Alessandra Retico, Flavio Nobili.   

Abstract

BACKGROUND: Medial temporal lobe (MTL) atrophy is one of the key biomarkers to detect early neurodegenerative changes in the course of Alzheimer's disease (AD). There is active research aimed at identifying automated methodologies able to extract accurate classification indexes from T1-weighted magnetic resonance images (MRI). Such indexes should be fit for identifying AD patients as early as possible.
SUBJECTS: A reference group composed of 144AD patients and 189 age-matched controls was used to train and test the procedure. It was then applied on a study group composed of 302 MCI subjects, 136 having progressed to clinically probable AD (MCI-converters) and 166 having remained stable or recovered to normal condition after a 24month follow-up (MCI-non converters). All subjects came from the ADNI database.
METHODS: We sampled the brain with 7 relatively small volumes, mainly centered on the MTL, and 2 control regions. These volumes were filtered to give intensity and textural MRI-based features. Each filtered region was analyzed with a Random Forest (RF) classifier to extract relevant features, which were subsequently processed with a Support Vector Machine (SVM) classifier. Once a prediction model was trained and tested on the reference group, it was used to compute a classification index (CI) on the MCI cohort and to assess its accuracy in predicting AD conversion in MCI patients. The performance of the classification based on the features extracted by the whole 9 volumes is compared with that derived from each single volume. All experiments were performed using a bootstrap sampling estimation, and classifier performance was cross-validated with a 20-fold paradigm.
RESULTS: We identified a restricted set of image features correlated with the conversion to AD. It is shown that most information originate from a small subset of the total available features, and that it is enough to give a reliable assessment. We found multiple, highly localized image-based features which alone are responsible for the overall clinical diagnosis and prognosis. The classification index is able to discriminate Controls from AD with an Area Under Curve (AUC)=0.97 (sensitivity ≃89% at specificity ≃94%) and Controls from MCI-converters with an AUC=0.92 (sensitivity ≃89% at specificity ≃80%). MCI-converters are separated from MCI-non converters with AUC=0.74(sensitivity ≃72% at specificity ≃65%).
FINDINGS: The present automated MRI-based technique revealed a strong relationship between highly localized baseline-MRI features and the baseline clinical assessment. In addition, the classification index was also used to predict the probability of AD conversion within a time frame of two years. The definition of a single index combining local analysis of several regions can be useful to detect AD neurodegeneration in a typical MCI population.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21718788     DOI: 10.1016/j.neuroimage.2011.05.083

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  41 in total

1.  Early detection of Alzheimer's disease using MRI hippocampal texture.

Authors:  Lauge Sørensen; Christian Igel; Naja Liv Hansen; Merete Osler; Martin Lauritzen; Egill Rostrup; Mads Nielsen
Journal:  Hum Brain Mapp       Date:  2015-12-21       Impact factor: 5.038

Review 2.  Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings.

Authors:  Meredith N Braskie; Paul M Thompson
Journal:  Trends Cogn Sci       Date:  2013-09-09       Impact factor: 20.229

3.  Magnetic resonance imaging texture predicts progression to dementia due to Alzheimer disease earlier than hippocampal volume

Authors:  Subin Lee; Hyunna Lee; Ki Woong Kim
Journal:  J Psychiatry Neurosci       Date:  2020-01-01       Impact factor: 6.186

4.  Description and classification of normal and pathological aging processes based on brain magnetic resonance imaging morphology measures.

Authors:  Jorge Luis Perez-Gonzalez; Oscar Yanez-Suarez; Ernesto Bribiesca; Fernando Arámbula Cosío; Juan Ramón Jiménez; Veronica Medina-Bañuelos
Journal:  J Med Imaging (Bellingham)       Date:  2014-10-07

5.  OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.

Authors:  James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2012-06

6.  Applying tensor-based morphometry to parametric surfaces can improve MRI-based disease diagnosis.

Authors:  Yalin Wang; Lei Yuan; Jie Shi; Alexander Greve; Jieping Ye; Arthur W Toga; Allan L Reiss; Paul M Thompson
Journal:  Neuroimage       Date:  2013-02-20       Impact factor: 6.556

7.  Manifold regularized multitask feature learning for multimodality disease classification.

Authors:  Biao Jie; Daoqiang Zhang; Bo Cheng; Dinggang Shen
Journal:  Hum Brain Mapp       Date:  2014-10-03       Impact factor: 5.038

Review 8.  Neuroimaging-based methods for autism identification: a possible translational application?

Authors:  Alessandra Retico; Michela Tosetti; Filippo Muratori; Sara Calderoni
Journal:  Funct Neurol       Date:  2014 Oct-Dec

Review 9.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

10.  Classification of mild cognitive impairment and Alzheimer disease using model-based MR and magnetization transfer imaging.

Authors:  R Wiest; Y Burren; M Hauf; G Schroth; J Pruessner; M Zbinden; K Cattapan-Ludewig; C Kiefer
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-11       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.